Search

The article discusses the potential for targeting systemic inflammation in patients with heart failure through leucocyte immunomodulation. It highlights the high incidence of cardiovascular mortality and hospitalizations for heart failure despite current therapies. The role of inflammation in heart failure is explored, with a focus on the involvement of proinflammatory cytokines and biomarkers. The article introduces a novel approach using a selective cytopheretic device (SCD) to target activated neutrophils and monocytes, which has shown promise in reducing systemic inflammation and improving outcomes in other acute conditions. A case report is presented to demonstrate the potential effectiveness of the SCD in bridging patients to left ventricular assist device (LVAD) implantation. The article concludes by suggesting that further studies are needed to evaluate the use of the SCD and its potential to reduce cardiovascular mortality and hospitalizations in heart failure patients. [Extracted from the article]

Currently described hyperkalemia (HK) animal models are typically acute and cause significant distress and mortality to the animals, warranting new approaches for studying chronic HK in a more appropriate clinical setting. Using the spontaneously hypertensive rat (SHR) model as a more relevant disease template, as well as surgical (unilateral nephrectomy), dietary (3% potassium [K+] supplementation), and pharmacological (amiloride) interventions, we were able to stably induce HK on a chronic basis for up to 12 weeks to serum K+ elevations between 8 and 9 mmol/L, with minimal clinical stress to the animals. Short‐term proof‐of‐concept and long‐term chronic studies in hyperkalemic SHRs showed concomitant increases in serum aldosterone, consistent with the previously reported relationship between serum K+ and aldosterone. Treatment with the K+ binder patiromer demonstrated that the disease model was responsive to pharmacological intervention, with significant abrogation in serum K+, as well as serum aldosterone to levels near baseline, and this was consistent in both short‐term and long‐term 12‐week chronic studies. Our results demonstrate the feasibility of establishing a chronic HK disease state, and this novel HK animal model may be suitable for further evaluating the effects of long‐term, K+‐lowering therapies on effects such as renal fibrosis and end‐organ damage. [ABSTRACT FROM AUTHOR]